Cannabichromene formulation for pain management
AssigneeZyus Life Sciences Inc.
InventorMahsa ABRISHAMI
Life of this patent
Estimating the term…
Abstract
A formulation for pain management is provided comprising cannabichromene as the primary cannabinoid together with an excipient and, optionally, one or more secondary cannabinoids in an amount of up to 5% by weight of the primary cannabinoid. The formulation is essentially free of tetrahydrocannabinol. The types of pain to be managed with the formulation include but are not limited to the treatment of neuropathic pain, pain due to cancer, injury, accident, surgery, or tissue damage. Methods of use of the formulation, doses and dosage forms are described.
Claims16
A formulation for use in pain management by a subject in need thereof, said formulation comprising a primary cannabinoid and one or more excipient, diluent, or carrier;
- wherein said primary cannabinoid consists of cannabichromene (CBC), and wherein said formulation is essentially free of tetrahydrocannabinol (THC).
A method for pain management in a subject in need thereof, comprising administering to said subject an effective amount of a formulation comprising a primary cannabinoid and one or more excipient, diluent or carrier;
- wherein said primary cannabinoid consists of cannabichromene (CBC), and wherein said formulation is essentially free of tetrahydrocannabinol (THC).
Dependencies are inferred from the claim text.